+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
End-stage Renal Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
End-stage Renal Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

End-stage Renal Disease Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6122743
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The End-stage Renal Disease Therapeutics Market is projected to reach USD 70.73 Billion in 2026. It is expected to continue growing at a CAGR of 4.17%, reaching USD 89.29 Billion by 2032.

End-Stage Renal Disease Therapeutics: Executive Overview

End-stage renal disease (ESRD) therapeutics encompasses medicines and supportive interventions used to manage patients with kidney failure receiving dialysis or awaiting transplantation. Treatment priorities include controlling anemia, mineral and bone disorders, fluid-related complications, cardiovascular risk, infections, and symptoms associated with advanced kidney dysfunction. Clinical decisions are shaped by dialysis modality, transplant eligibility, comorbidities, treatment access, and national reimbursement systems.

How ESRD Care Is Being Transformed

The therapeutic landscape is shifting from isolated symptom control toward integrated, patient-centered management across dialysis, transplantation, and supportive care. Longer-acting anemia therapies, more individualized iron strategies, phosphate-control approaches, calcimimetic use, and improved management of cardiovascular and metabolic complications are influencing treatment pathways. At the same time, home dialysis, remote monitoring, multidisciplinary care, and efforts to improve medication adherence are changing how therapy is delivered.

Artificial Intelligence Across ESRD Therapeutics

Artificial intelligence is increasingly relevant to ESRD care through risk stratification, dialysis-quality monitoring, medication-support tools, and identification of patients at risk of hospitalization or treatment complications. Machine-learning systems may help interpret longitudinal laboratory, vital-sign, and treatment data, while clinical decision support can assist with anemia management, fluid assessment, and transplant evaluation. Responsible implementation requires representative data, clinician oversight, transparent validation, privacy safeguards, and careful monitoring for bias across populations and care settings.

Regional Insights Across the ESRD Treatment Landscape

North America combines advanced dialysis infrastructure, specialized nephrology services, and broad access to innovative therapies, although affordability and unequal access remain important concerns. Europe reflects diverse national reimbursement and procurement models, with strong emphasis on clinical guidelines, safety, and integrated chronic-care pathways. Asia-Pacific includes highly developed systems alongside rapidly expanding dialysis capacity, creating substantial variation in access, workforce availability, and treatment continuity. Latin America continues to face differences in coverage, infrastructure, and transplant availability. The Middle East is investing in specialized renal services while addressing workforce and access disparities. Africa experiences pronounced constraints in dialysis availability, medicine supply, transplantation, and early detection, making scalable and affordable care models especially important.

Insights Across ASEAN, BRICS, EU, G7, GCC, and NATO Groups

ASEAN markets show wide variation in health financing, dialysis capacity, and availability of specialist medicines, supporting the need for adaptable regional care models. BRICS members span large and diverse patient populations with differing public-private delivery systems, domestic manufacturing capabilities, and access conditions. The European Union benefits from coordinated regulatory principles but retains national differences in reimbursement and service organization. G7 countries generally possess mature nephrology infrastructure and established research networks, while continuing to address aging populations, multimorbidity, and treatment burden. GCC states have invested substantially in specialized healthcare capacity, though workforce development and dependence on imported therapies remain relevant. NATO members include highly varied health systems, making common priorities such as resilient supply chains, emergency preparedness, and cross-border clinical collaboration significant.

Country-Level Priorities in ESRD Therapeutics

Australia emphasizes coordinated chronic-kidney care, dialysis access, and transplantation across geographically dispersed communities. Brazil continues to balance a large public health system with regional differences in dialysis and transplant access. Canada focuses on equitable access across provinces and remote communities. China is expanding renal-care capacity while strengthening insurance coverage, clinical standardization, and domestic innovation. France, Germany, Italy, and Spain operate within mature European systems but differ in reimbursement, procurement, dialysis organization, and transplant pathways. India faces substantial variation in affordability, specialist availability, and access between urban and rural populations. Japan combines advanced dialysis expertise with the challenges of population aging and prolonged treatment needs. Mexico continues to address uneven access, infrastructure constraints, and the burden of diabetes-related kidney disease. Russia’s care environment reflects geographic scale, resource distribution, and access considerations. South Korea has developed sophisticated renal services while managing aging and chronic disease. The United Kingdom emphasizes guideline-based care, outcomes monitoring, and equitable access across its devolved health systems. The United States combines extensive specialty infrastructure and therapeutic choice with persistent concerns regarding affordability, care fragmentation, and disparities.

Strategic Priorities for ESRD Therapeutics Leaders

Industry leaders should prioritize therapies that reduce treatment burden, support adherence, and address anemia, mineral and bone disorders, cardiovascular complications, and inflammation within clearly defined patient populations. Evidence generation should reflect real-world dialysis settings, older adults, comorbid patients, and underserved communities rather than relying only on narrowly selected trial populations. Partnerships with providers and health systems can improve care pathways, monitoring, patient education, and home-based treatment support. Supply-chain resilience, responsible pricing, regulatory readiness, and post-market safety surveillance are essential. Organizations should also establish governance frameworks for artificial intelligence, including validation, explainability, cybersecurity, and clinician accountability.

Research Methodology for the ESRD Therapeutics Executive Summary

This executive summary uses a structured review of the ESRD therapeutic context, focusing on disease-management priorities, treatment delivery, health-system variation, technology adoption, and access considerations. Insights are synthesized narratively from established clinical and public-health principles rather than from market estimation or forecasting. Regional, country, and group comparisons are framed around documented differences in healthcare infrastructure, reimbursement, epidemiology, specialist capacity, transplantation, and dialysis delivery. Interpretations should be validated against current clinical guidelines, regulatory information, peer-reviewed evidence, and national health-system data before being used for investment or clinical decisions.

Conclusion: Building More Integrated and Equitable ESRD Care

ESRD therapeutics is evolving toward coordinated management that links medicines, dialysis services, transplantation, monitoring, and supportive care. Progress will depend not only on pharmacological innovation but also on affordability, reliable supply, clinical workforce capacity, patient-centered delivery, and evidence that reflects diverse populations. Artificial intelligence can strengthen this ecosystem when deployed with robust safeguards and human oversight. Leaders that combine therapeutic value with measurable improvements in access, adherence, safety, and care continuity will be best positioned to contribute to better outcomes across varied health systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. End-stage Renal Disease Therapeutics Market, by Therapy Type
7.1. Introduction
7.2. Drug Therapy
7.2.1. Calcimimetics
7.2.2. Erythropoiesis Stimulating Agents
7.2.3. Iron Therapies
7.2.4. Phosphate Binders
7.2.5. Vitamin D Analogs
7.3. Renal Replacement Therapy
7.3.1. Hemodialysis
7.3.2. Peritoneal Dialysis
7.3.2.1. Automated
7.3.2.2. Continuous Ambulatory
7.3.3. Transplant
8. End-stage Renal Disease Therapeutics Market, by End User
8.1. Introduction
8.2. Dialysis Centers
8.3. Home Care Settings
8.4. Hospitals
9. End-stage Renal Disease Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. End-stage Renal Disease Therapeutics Market, by Region
10.1. Introduction
10.2. Asia-Pacific
10.3. North America
10.4. Latin America
10.5. Europe
10.6. Middle East
10.7. Africa
11. End-stage Renal Disease Therapeutics Market, by Group
11.1. Introduction
11.2. ASEAN
11.3. GCC
11.4. European Union
11.5. BRICS
11.6. G7
11.7. NATO
12. End-stage Renal Disease Therapeutics Market, by Country
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. United Kingdom
12.7. Germany
12.8. France
12.9. Russia
12.10. Italy
12.11. Spain
12.12. China
12.13. India
12.14. Japan
12.15. Australia
12.16. South Korea
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. Market Concentration Analysis, 2025
13.2.1. Concentration Ratio (CR)
13.2.2. Herfindahl Hirschman Index (HHI)
13.3. Recent Developments & Impact Analysis, 2025
13.4. Product Portfolio Analysis, 2025
13.5. Benchmarking Analysis, 2025
14. Company Profiles
14.1. Amgen Inc.
14.2. Asahi Kasei Corporation
14.3. AstraZeneca plc
14.4. B. Braun Melsungen AG
14.5. Baxter International Inc.
14.6. Bayer AG
14.7. Cantel Medical Corporation
14.8. DaVita Inc.
14.9. Eli Lilly and Company
14.10. F. Hoffmann-La Roche Ltd
14.11. Fresenius Kabi
14.12. Fresenius Medical Care AG & Co. KGaA
14.13. GlaxoSmithKline plc
14.14. JMS Co., Ltd.
14.15. Johnson & Johnson
14.16. Kyowa Kirin Co., Ltd.
14.17. Medtronic plc
14.18. Mitsubishi Tanabe Pharma Corporation
14.19. Nikkiso Co., Ltd.
14.20. Nipro Corporation
14.21. Novartis AG
14.22. NxStage Medical, Inc.
14.23. Otsuka Pharmaceutical Co., Ltd.
14.24. Pfizer Inc.
14.25. Rockwell Medical, Inc.
14.26. Sanofi S.A.
14.27. Takeda Pharmaceutical Company Limited
14.28. Toray Medical Co., Ltd.
14.29. Vifor Pharma Group Ltd
15. Key Experts
LIST OF FIGURES
FIGURE 1. Global End-stage Renal Disease Therapeutics Market, Years Considered for the Study
FIGURE 2. Global End-stage Renal Disease Therapeutics Market, Research Design
FIGURE 3. Global End-stage Renal Disease Therapeutics Market, Research Framework
FIGURE 4. Global End-stage Renal Disease Therapeutics Market, Data Triangulation
FIGURE 5. Global End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global End-stage Renal Disease Therapeutics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 9. Global End-stage Renal Disease Therapeutics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global End-stage Renal Disease Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 13. Global End-stage Renal Disease Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global End-stage Renal Disease Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 15. Global End-stage Renal Disease Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 16. Global End-stage Renal Disease Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global End-stage Renal Disease Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global End-stage Renal Disease Therapeutics Market Segmentation & Coverage
TABLE 2. Global End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Drug Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Drug Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Drug Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Calcimimetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Calcimimetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Calcimimetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Erythropoiesis Stimulating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Erythropoiesis Stimulating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Erythropoiesis Stimulating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Iron Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Iron Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Iron Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Phosphate Binders Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Phosphate Binders Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Phosphate Binders Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Vitamin D Analogs Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Vitamin D Analogs Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Vitamin D Analogs Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Renal Replacement Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Renal Replacement Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Renal Replacement Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Hemodialysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Hemodialysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Hemodialysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Peritoneal Dialysis Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Peritoneal Dialysis Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Peritoneal Dialysis Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Automated Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Automated Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Automated Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Continuous Ambulatory Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Continuous Ambulatory Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Continuous Ambulatory Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Transplant Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Transplant Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Transplant Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 41. Global Dialysis Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Dialysis Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Dialysis Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 51. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 68. North America End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. North America End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 70. North America End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 71. North America End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 72. North America End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 73. North America End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. North America End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Latin America End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Latin America End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 77. Latin America End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 78. Latin America End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 79. Latin America End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 80. Latin America End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Latin America End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Europe End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Europe End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 84. Europe End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 85. Europe End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 86. Europe End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 87. Europe End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 88. Europe End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 89. Middle East End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 91. Middle East End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 92. Middle East End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 93. Middle East End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 94. Middle East End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Middle East End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Africa End-stage Renal Disease Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Africa End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 98. Africa End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 99. Africa End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 100. Africa End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 101. Africa End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Africa End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. Global End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. ASEAN End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. ASEAN End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 106. ASEAN End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 107. ASEAN End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 108. ASEAN End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 109. ASEAN End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. ASEAN End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. GCC End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. GCC End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 113. GCC End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 114. GCC End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 115. GCC End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 116. GCC End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. GCC End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 118. European Union End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. European Union End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 120. European Union End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 121. European Union End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 122. European Union End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 123. European Union End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. European Union End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. BRICS End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. BRICS End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 127. BRICS End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 128. BRICS End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 129. BRICS End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 130. BRICS End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. BRICS End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. G7 End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. G7 End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 134. G7 End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 135. G7 End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 136. G7 End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 137. G7 End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. G7 End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. NATO End-stage Renal Disease Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. NATO End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 141. NATO End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 142. NATO End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 143. NATO End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 144. NATO End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. NATO End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Global End-stage Renal Disease Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. United States End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 148. United States End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 149. United States End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 150. United States End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 151. United States End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 152. United States End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. United States End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. Canada End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 155. Canada End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 156. Canada End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 157. Canada End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 158. Canada End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 159. Canada End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Canada End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. Mexico End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 162. Mexico End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 163. Mexico End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 164. Mexico End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 165. Mexico End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 166. Mexico End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Mexico End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Brazil End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 169. Brazil End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 170. Brazil End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 171. Brazil End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 172. Brazil End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 173. Brazil End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. Brazil End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. United Kingdom End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 176. United Kingdom End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 177. United Kingdom End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 178. United Kingdom End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 179. United Kingdom End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 180. United Kingdom End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. United Kingdom End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. Germany End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 183. Germany End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 184. Germany End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 185. Germany End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 186. Germany End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 187. Germany End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. Germany End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. France End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 190. France End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 191. France End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 192. France End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 193. France End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 194. France End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. France End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Russia End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 197. Russia End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 198. Russia End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 199. Russia End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 200. Russia End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 201. Russia End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Russia End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Italy End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 204. Italy End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 205. Italy End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 206. Italy End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 207. Italy End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 208. Italy End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Italy End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Spain End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 211. Spain End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 212. Spain End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 213. Spain End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 214. Spain End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 215. Spain End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. Spain End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. China End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 218. China End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 219. China End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 220. China End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 221. China End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 222. China End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. China End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. India End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 225. India End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 226. India End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 227. India End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 228. India End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 229. India End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. India End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 231. Japan End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 232. Japan End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 233. Japan End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 234. Japan End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 235. Japan End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 236. Japan End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Japan End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. Australia End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 239. Australia End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 240. Australia End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 241. Australia End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 242. Australia End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 243. Australia End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Australia End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. South Korea End-stage Renal Disease Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 246. South Korea End-stage Renal Disease Therapeutics Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 247. South Korea End-stage Renal Disease Therapeutics Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 248. South Korea End-stage Renal Disease Therapeutics Market Size, by Renal Replacement Therapy, 2017-2032 (USD Million)
TABLE 249. South Korea End-stage Renal Disease Therapeutics Market Size, by Peritoneal Dialysis, 2017-2032 (USD Million)
TABLE 250. South Korea End-stage Renal Disease Therapeutics Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. South Korea End-stage Renal Disease Therapeutics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. Global End-stage Renal Disease Therapeutics Market Share, by Key Player, 2025
TABLE 253. Global End-stage Renal Disease Therapeutics Market, Key Experts

Companies Mentioned

  • Amgen Inc.
  • Asahi Kasei Corporation
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • Cantel Medical Corporation
  • DaVita Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc
  • JMS Co., Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Medtronic plc
  • Mitsubishi Tanabe Pharma Corporation
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Rockwell Medical, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Toray Medical Co., Ltd.
  • Vifor Pharma Group Ltd

Related Topics

Related Reports

End-Stage Renal Disease - Global Strategic Business Report - Product Image

End-Stage Renal Disease - Global Strategic Business Report

  • Report
  • 174 Pages
  • Global
From
End Stage Renal Disease Market - Global Forecast 2026-2032 - Product Image

End Stage Renal Disease Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
End Stage Renal Disease (ESRD) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

End Stage Renal Disease (ESRD) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 135 Pages
  • Global
From
End Stage Renal Disease Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment (Kidney Transplantation, Dialysis, Hemodialysis, Peritoneal Dialysis, Conservative Kidney Management), Diagnosis, End User, Product Type - Product Image

End Stage Renal Disease Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment (Kidney Transplantation, Dialysis, Hemodialysis, Peritoneal Dialysis, Conservative Kidney Management), Diagnosis, End User, Product Type

  • Report
  • 160 Pages
  • Global
From
Diabetic Nephropathy Treatment Market - Global Forecast 2026-2032 - Product Image

Diabetic Nephropathy Treatment Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.